CU20190005A7 - Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico - Google Patents
Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéuticoInfo
- Publication number
- CU20190005A7 CU20190005A7 CU2019000005A CU20190005A CU20190005A7 CU 20190005 A7 CU20190005 A7 CU 20190005A7 CU 2019000005 A CU2019000005 A CU 2019000005A CU 20190005 A CU20190005 A CU 20190005A CU 20190005 A7 CU20190005 A7 CU 20190005A7
- Authority
- CU
- Cuba
- Prior art keywords
- chewing gum
- orally administrable
- pharmaceutical agent
- aqueous formulations
- formulations including
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 4
- 229940112822 chewing gum Drugs 0.000 title abstract 2
- 235000015218 chewing gum Nutrition 0.000 title abstract 2
- 239000013011 aqueous formulation Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229930003827 cannabinoid Natural products 0.000 abstract 1
- 239000003557 cannabinoid Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Confectionery (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Se proporciona una formulación de goma de mascar o formulación de base acuosa administrable por vía oral, que comprende una o más partículas que contienen agentes farmacéuticos que proporcionan una liberación rápida de los agentes farmacéuticos para su absorción en el sistema circulatorio de un mamífero. Las presentes formulaciones proporcionan un medio alternativo aceptable para administrar agentes farmacéuticos como los derivados de cannabinoides para el tratamiento del dolor y otras dolencias.</p> <p> </p> <p> </p>
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/222,019 US9833408B1 (en) | 2016-07-28 | 2016-07-28 | Orally administrable formulation |
PCT/CA2017/050904 WO2018018152A1 (en) | 2016-07-28 | 2017-07-28 | Novel orally administrable formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20190005A7 true CU20190005A7 (es) | 2020-03-04 |
Family
ID=60451833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2019000005A CU20190005A7 (es) | 2016-07-28 | 2017-07-28 | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico |
Country Status (13)
Country | Link |
---|---|
US (2) | US9833408B1 (es) |
EP (2) | EP3490539B1 (es) |
JP (2) | JP7050777B2 (es) |
AU (2) | AU2017301239B2 (es) |
BR (2) | BR112019001572B1 (es) |
CL (1) | CL2019000209A1 (es) |
CO (1) | CO2019001895A2 (es) |
CU (1) | CU20190005A7 (es) |
IL (1) | IL264484A (es) |
MX (1) | MX2019001169A (es) |
PE (1) | PE20190738A1 (es) |
WO (1) | WO2018018152A1 (es) |
ZA (2) | ZA201901116B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9833408B1 (en) * | 2016-07-28 | 2017-12-05 | Allen Greenspoon | Orally administrable formulation |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
US11449887B2 (en) | 2017-10-09 | 2022-09-20 | American Express Travel Related Services Company, Inc. | Systems and methods for loyalty point distribution |
US11699166B2 (en) | 2017-10-09 | 2023-07-11 | American Express Travel Related Services Company, Inc. | Multi-merchant loyalty point partnership |
US11397962B2 (en) | 2017-10-09 | 2022-07-26 | American Express Travel Related Services Company, Inc. | Loyalty point distributions using a decentralized loyalty ID |
WO2019152736A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
EP3549579A1 (en) * | 2018-04-03 | 2019-10-09 | Sanofi Winthrop Industrie | Oral gum formulation and fabrication process thereof |
MX2020010424A (es) * | 2018-04-03 | 2021-01-15 | Pure Green Pharmaceuticals Inc | Comprimido o composicion que contiene n-acil etanolamina y cannabinoides. |
US11728995B2 (en) | 2018-04-09 | 2023-08-15 | American Express Travel Related Services Company, Inc. | Reward point transfers using blockchain |
US10783545B2 (en) | 2018-04-19 | 2020-09-22 | American Express Travel Related Services Company, Inc. | Reward point redemption for cryptocurrency |
US11040932B2 (en) | 2018-10-10 | 2021-06-22 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
US11406593B2 (en) | 2019-01-25 | 2022-08-09 | Nordiccan A/S | Cannabinoid chewing gum with high intensity sweeteners |
US11154496B2 (en) * | 2019-01-25 | 2021-10-26 | Nordiccan A/S | Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers |
PL3876743T3 (pl) * | 2019-01-25 | 2023-08-28 | Nordiccan A/S | Kannabinoidowa guma do żucia z alkoholami cukrowymi |
US11166910B2 (en) | 2019-01-25 | 2021-11-09 | Nordiccan A/S | Cannabinoid chewing gum with sugar alcohols |
WO2020151793A1 (en) * | 2019-01-25 | 2020-07-30 | Medcan Pharma A/S | Chewing gum with improved delivery of cannabinoids |
US11191720B2 (en) | 2019-01-25 | 2021-12-07 | Nordiccan A/S | Chewing gum with improved delivery of cannabinoids |
EP3914088A1 (en) * | 2019-01-25 | 2021-12-01 | NordicCan A/S | Cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers |
US11013685B2 (en) * | 2019-01-25 | 2021-05-25 | Nordiccan A/S | Cannabinoid chewing gum with improved release of cannabinoids |
AU2019424547B2 (en) * | 2019-01-25 | 2023-06-22 | Nordiccan A/S | Cannabinoid chewing gum with improved release of cannabinoids |
DK3876742T3 (da) * | 2019-01-25 | 2023-05-01 | Nordiccan As | Cannabinoidtyggegummi med højintensive sødemidler |
US10799450B2 (en) | 2019-03-01 | 2020-10-13 | Medcan Pharma A/S | Tableted cannabinoid chewing gum with layered structure |
US10933017B2 (en) | 2019-03-01 | 2021-03-02 | Nordiccan A/S | Tableted cannabinoid chewing gum with polyvinyl acetate elastomer plasticizers |
US11471405B2 (en) | 2019-03-01 | 2022-10-18 | Nordiccan A/S | Tableted chewing gum with enhanced delivery of cannabinoids |
US11253473B2 (en) * | 2019-03-01 | 2022-02-22 | Nordiccan A/S | Method of producing tableted cannabinoid chewing gum |
US11331309B2 (en) | 2019-06-05 | 2022-05-17 | Cure Pharmaceutical Holding Corp. | Methods and compositions for improving sleep |
US20220273558A1 (en) * | 2019-08-02 | 2022-09-01 | Advanced Female Technologies Llc | Chewing Gum Compositions Containing Cannabinoids |
WO2021084543A1 (en) * | 2019-10-31 | 2021-05-06 | M. Mustix Ltd | Treatment of tooth decay using a chewing gum composition comprising cannabinoids |
EP4072516A1 (en) | 2019-12-09 | 2022-10-19 | Nicoventures Trading Limited | Oral product comprising a cannabinoid |
WO2021116825A1 (en) * | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product |
WO2022072031A1 (en) | 2020-10-01 | 2022-04-07 | Tobacco Technology, Inc. | Shisha, heat-not-burn, or combustion casing, product, and method of making the same |
US11058142B1 (en) | 2020-10-01 | 2021-07-13 | Tobacco Technology, Inc. | Shisha, heat-not-burn, or combustion casing with active ingredient, product and casing with active ingredient, and method of making the same |
US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
WO2022103634A1 (en) * | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Improved use of cannabinoids in the treatment of epilepsy |
US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
WO2023272335A1 (en) * | 2021-06-30 | 2023-01-05 | Emyria | Cannabidiol formulation comprising a matrix pellet forming excipient |
CA3234805A1 (en) * | 2021-10-11 | 2023-04-20 | C. Russell Thomas | Biphasic compositions comprising one or both of carbonate and phosphate |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816265A (en) * | 1986-12-23 | 1989-03-28 | Warner-Lambert Company | Sweetener delivery systems containing polyvinyl acetate |
DK505588D0 (da) * | 1988-02-26 | 1988-09-09 | Jesper Hamburger | Middel og anvendelse af samme |
US6132762A (en) * | 1997-05-05 | 2000-10-17 | Cristobal; Walter | Transcutaneous application of marijuana |
US7648696B2 (en) * | 1999-08-20 | 2010-01-19 | Unimed Pharmaceuticals, Llc | Composition for inhalation comprising delta-9-tetrahydrocannabinol in a semiaqueous solvent |
AU782991B2 (en) * | 2000-03-09 | 2005-09-15 | GW Research Limited | Pharmaceutical compositions |
US7357943B2 (en) * | 2000-12-07 | 2008-04-15 | Nycomed Gmbh | Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient |
DE10296335T5 (de) * | 2001-02-14 | 2004-04-15 | G W Pharma Ltd., Salisbury | Pharmazeutische Formulierungen |
DE10109763A1 (de) * | 2001-02-28 | 2002-09-05 | Gruenenthal Gmbh | Pharmazeutische Salze |
US6503532B1 (en) * | 2001-04-13 | 2003-01-07 | Murty Pharmaceuticals, Inc. | Pharmaceutical composition containing tetrahydrocannabinol and a transdermal/transcutaneous delivery method thereof |
GB2391865B (en) * | 2002-08-14 | 2005-06-01 | Gw Pharma Ltd | Improvements in the extraction of pharmaceutically active components from plant materials |
US6946150B2 (en) * | 2002-08-14 | 2005-09-20 | Gw Pharma Limited | Pharmaceutical formulation |
US8911751B2 (en) * | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
EP2046290A4 (en) * | 2006-08-04 | 2011-08-17 | Insys Therapeutics Inc | AQUEOUS DRONABINOL FORMULATIONS |
US20090181080A1 (en) * | 2007-08-06 | 2009-07-16 | Insys Therapeutics Inc. | Oral cannabinnoid liquid formulations and methods of treatment |
BRPI0910094B1 (pt) * | 2008-03-26 | 2021-08-10 | Stichting Sanammad | Composição de goma de mascar, e, blíster |
MX2011002121A (es) * | 2008-08-29 | 2011-05-10 | Sun Pharma Advanced Res Co Ltd | Microparticulas. |
JP5614571B2 (ja) * | 2009-12-25 | 2014-10-29 | ダイヤ製薬株式会社 | 咀嚼用ガム医薬品および咀嚼用ガム医薬品の製造方法 |
MX350871B (es) * | 2011-02-28 | 2017-09-19 | Tech Khloros Inc | Vehiculo masticable para absorcion bucal. |
WO2013009928A1 (en) * | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
EP2968259B1 (en) * | 2013-03-14 | 2022-09-14 | SC Laboratories Inc. | Bioactive concentrates and uses thereof |
US20160199299A1 (en) * | 2015-01-09 | 2016-07-14 | Mark B. Uren | Cannabis Infused Chewing Composition |
CN105124747B (zh) * | 2015-07-21 | 2018-04-10 | 中国烟草总公司广东省公司 | 一种烟草提取物微粒和胶基型口香烟及其制备方法 |
WO2017202424A1 (en) * | 2016-05-27 | 2017-11-30 | Medcan Pharma A/S | Powdered composition comprising a complex between a cannabinoid and a basic ion exchange resin |
US9833408B1 (en) * | 2016-07-28 | 2017-12-05 | Allen Greenspoon | Orally administrable formulation |
CA3028160C (en) * | 2016-07-28 | 2021-03-30 | Allen Greenspoon | Orally administrable formulation |
-
2016
- 2016-07-28 US US15/222,019 patent/US9833408B1/en active Active
-
2017
- 2017-07-28 AU AU2017301239A patent/AU2017301239B2/en active Active
- 2017-07-28 PE PE2019000281A patent/PE20190738A1/es unknown
- 2017-07-28 EP EP17833153.4A patent/EP3490539B1/en active Active
- 2017-07-28 WO PCT/CA2017/050904 patent/WO2018018152A1/en active Application Filing
- 2017-07-28 EP EP24160275.4A patent/EP4353221A2/en active Pending
- 2017-07-28 JP JP2019526350A patent/JP7050777B2/ja active Active
- 2017-07-28 BR BR112019001572-8A patent/BR112019001572B1/pt active IP Right Grant
- 2017-07-28 BR BR122020007418-3A patent/BR122020007418B1/pt active IP Right Grant
- 2017-07-28 CU CU2019000005A patent/CU20190005A7/es unknown
- 2017-07-28 MX MX2019001169A patent/MX2019001169A/es unknown
- 2017-11-08 US US15/806,928 patent/US10456357B2/en active Active
-
2019
- 2019-01-25 CL CL2019000209A patent/CL2019000209A1/es unknown
- 2019-01-27 IL IL264484A patent/IL264484A/en unknown
- 2019-02-21 ZA ZA2019/01116A patent/ZA201901116B/en unknown
- 2019-02-27 CO CONC2019/0001895A patent/CO2019001895A2/es unknown
-
2020
- 2020-02-19 ZA ZA2020/01037A patent/ZA202001037B/en unknown
- 2020-10-21 AU AU2020257071A patent/AU2020257071B2/en active Active
-
2022
- 2022-03-29 JP JP2022054535A patent/JP2022088537A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA201901116B (en) | 2020-10-28 |
EP3490539A4 (en) | 2020-08-12 |
CL2019000209A1 (es) | 2019-09-27 |
MX2019001169A (es) | 2019-08-29 |
ZA202001037B (en) | 2020-07-29 |
AU2017301239A1 (en) | 2019-03-14 |
IL264484A (en) | 2019-02-28 |
US10456357B2 (en) | 2019-10-29 |
WO2018018152A1 (en) | 2018-02-01 |
JP2019525963A (ja) | 2019-09-12 |
US9833408B1 (en) | 2017-12-05 |
AU2020257071B2 (en) | 2021-03-25 |
AU2020257071A1 (en) | 2020-11-19 |
JP2022088537A (ja) | 2022-06-14 |
CO2019001895A2 (es) | 2019-05-31 |
BR112019001572B1 (pt) | 2021-11-03 |
EP4353221A2 (en) | 2024-04-17 |
JP7050777B2 (ja) | 2022-04-08 |
PE20190738A1 (es) | 2019-05-23 |
BR112019001572A2 (pt) | 2019-05-07 |
US20180064645A1 (en) | 2018-03-08 |
BR122020007418B1 (pt) | 2021-11-03 |
EP3490539B1 (en) | 2024-03-13 |
EP3490539A1 (en) | 2019-06-05 |
AU2017301239B2 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20190005A7 (es) | Goma de mascar administrable oralmente o formulaciones acuosas que comprenden un agente farmacéutico | |
NZ726746A (en) | Stable cannabinoid formulations | |
CL2017002817A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
CL2015003072A1 (es) | Formulaciones de liberación prolongada de colchicina y métodos de uso de las mismas. | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
BR112015018095A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
BR112019001921A2 (pt) | moduladores do receptor nmda de espiro-lactama e seus usos | |
CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
DOP2017000307A (es) | Formulación sólida oral que contiene irinotecán y método de preparación de la misma. | |
BR112016026667A8 (pt) | comprimido oralmente desintegrante para administração de avanafil, métodos associados de fabricação e uso de um inibidor de pde v | |
CL2018003682A1 (es) | Composición farmacéutica oral, que comprende un agente farmacéuticamente activo, al menos un polímero catiónico bioadhesivo y al menos dos polímeros aniónicos. | |
PE20151607A1 (es) | Formulaciones de compuestos organicos | |
BR112019007539A2 (pt) | formulações para liberação entérica de agentes terapêuticos | |
AR109693A1 (es) | Formulaciones de liberación inmediata de oprozomib | |
CO2017000354A2 (es) | Desmopresina estabilizada | |
CL2019001462A1 (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla. | |
AR104504A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
AR099330A1 (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
ECSP19044926A (es) | Composición mejorada de lansoprazol y simeticona y proceso para prepararla | |
CO2020002287A2 (es) | Composiciones farmacéuticas | |
AR106029A1 (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue |